Latest & greatest articles for Benign Prostatic Hyperplasia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Benign Prostatic Hyperplasia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Benign Prostatic Hyperplasia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Benign Prostatic Hyperplasia

61. Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review

Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

62. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis

Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

63. WITHDRAWN: Tamsulosin for benign prostatic hyperplasia. (Abstract)

WITHDRAWN: Tamsulosin for benign prostatic hyperplasia. Benign prostatic hyperplasia (BPH) is a nonmalignant enlargement of the prostate which can result in bothersome lower urinary tract symptoms. The treatment goal for men with BPH is to relieve these bothersome symptoms.This systematic review assessed the effects of tamsulosin in the treatment of lower urinary tract symptoms (LUTS) compatible with BPH.Trials were searched in computerized general and specialized databases (MEDLINE, EMBASE

2011 Cochrane

64. WITHDRAWN: Terazosin for benign prostatic hyperplasia. (Abstract)

WITHDRAWN: Terazosin for benign prostatic hyperplasia. Lower urinary tract symptoms associated with benign prostatic obstruction (BPO) occur in up to 70% of men over the age of 60 years. To relieve these bothersome symptoms, treatment options include alpha-antagonists, also know as alpha-blockers.We conducted a systematic review to evaluate the effectiveness and adverse effects of the alpha-blocker, terazosin, for treatment of urinary symptoms associated with BPO.Trials were searched (...) to other alpha antagonists. The pooled mean percentage improvements for the Boyarsky symptom score was 37% for terazosin versus 15% for placebo (n = 4 studies). The mean percentage improvement for the American Urological Association symptom score (AUA) was 38% compared to 17% and 20% for placebo and finasteride, respectively (n = 2 studies). The pooled mean improvement in the International Prostate Symptom Score (IPSS) (40%) was similar to tamsulosin (43%). Peak urine flow rates improved greater

2011 Cochrane

65. Bipolar plasmakinetic electrovaporization for benign prostatic hyperplasia (BPH)

Bipolar plasmakinetic electrovaporization for benign prostatic hyperplasia (BPH) Bipolar plasmakinetic electrovaporization for benign prostatic hyperplasia (BPH) Bipolar plasmakinetic electrovaporization for benign prostatic hyperplasia (BPH) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bipolar plasmakinetic electrovaporization for benign prostatic (...) hyperplasia (BPH) Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2011 Authors' objectives Transurethral resection of the prostate (TURP) is considered the standard surgical therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH). Its high success rate is reflected by substantial improvements in symptom scores, urinary flow rate, postvoid residual (PVR) urine volume, and a low retreatment on long-term follow-up. However, TURP is associated with significant

2011 Health Technology Assessment (HTA) Database.

66. WITHDRAWN: Cernilton for benign prostatic hyperplasia. (Abstract)

WITHDRAWN: Cernilton for benign prostatic hyperplasia. Benign prostatic hyperplasia (BPH), nonmalignant enlargement of the prostate, can lead to obstructive and irritative lower urinary tract symptoms (LUTS). The pharmacologic use of plants and herbs (phytotherapy) for the treatment of LUTS associated with BPH has been growing steadily. Cernilton, prepared from the rye-grass pollen Secale cereale, is one of the several phytotherapeutic agents available for the treatment of BPH.This systematic (...) review aims to assess the effects of Cernilton on urinary symptoms and flow measures in men with benign prostatic hyperplasia (BPH).Trials were searched in computerized general and specialized databases (MEDLINE, EMBASE, Cochrane Library, Phytodok), by checking bibliographies, and by contacting manufacturers and researchers.Trials were eligible if they were: (1) randomized controlled trials or controlled clinical trials comparing Cernilton with placebo or other BPH medications in men with BPH; and (2

2011 Cochrane

67. [Economic evaluation of photoselective vaporization treatment for benign prostatic hyperplasia]

[Economic evaluation of photoselective vaporization treatment for benign prostatic hyperplasia] Evaluación económica de la vaporización fotoselectiva de la próstata para el tratamiento de la hiperplasia benigna de próstata [Economic evaluation of photoselective vaporization treatment for benign prostatic hyperplasia] Evaluación económica de la vaporización fotoselectiva de la próstata para el tratamiento de la hiperplasia benigna de próstata [Economic evaluation of photoselective vaporization (...) treatment for benign prostatic hyperplasia] Callejo-Velasco D, López-Polín D´Olhaberriague A, Guerra-Rodríguez M, Blasco-Amaro JA Citation Callejo-Velasco D, López-Polín D´Olhaberriague A, Guerra-Rodríguez M, Blasco-Amaro JA. Evaluación económica de la vaporización fotoselectiva de la próstata para el tratamiento de la hiperplasia benigna de próstata. [Economic evaluation of photoselective vaporization treatment for benign prostatic hyperplasia] Unidad de Evaluacion de Tecnologias Sanitarias (UETS

2010 Health Technology Assessment (HTA) Database.

68. Efficacy and safety of tamsulosin for the treatment of benign prostatic hyperplasia: a meta analysis

Efficacy and safety of tamsulosin for the treatment of benign prostatic hyperplasia: a meta analysis Efficacy and safety of tamsulosin for the treatment of benign prostatic hyperplasia: a meta analysis Efficacy and safety of tamsulosin for the treatment of benign prostatic hyperplasia: a meta analysis Ren RM, Kou M, Lan XX CRD summary This review concluded that in comparison with placebo, tamsulosin improved international prostate symptom scores and maximum flow rates for patients with benign (...) prostatic hyperplasia with no significant difference in adverse events. A risk of missing data, paucity of evidence and a lack of information regarding study quality suggest that the findings should be interpreted with caution. Authors' objectives To determine the safety and efficacy of tamsulosin compared with placebo for the treatment of benign prostatic hyperplasia (BPH). Searching PubMed, EBSCO, CBM and CNKI were searched up to 2008. Search terms were reported. Science Direct and four relevant

2010 DARE.

69. [Laser treatment for benign prostatic hyperplasia. Proposal of assessment indicators]

[Laser treatment for benign prostatic hyperplasia. Proposal of assessment indicators] Tratamiento de la hiperplasia benigna de prostata mediante laser. Propuesta de indicadores para su evaluacion [Laser treatment for benign prostatic hyperplasia. Proposal of assessment indicators] Tratamiento de la hiperplasia benigna de prostata mediante laser. Propuesta de indicadores para su evaluacion [Laser treatment for benign prostatic hyperplasia. Proposal of assessment indicators] Paz Valinas L, Queiro (...) Verdes T Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Paz Valinas L, Queiro Verdes T. Tratamiento de la hiperplasia benigna de prostata mediante laser. Propuesta de indicadores para su evaluacion. [Laser treatment for benign prostatic hyperplasia. Proposal of assessment indicators] Santiago de Compostela: Galician Agency for Health

2010 Health Technology Assessment (HTA) Database.

70. Laser therapy for benign prostatic hyperplasia

Laser therapy for benign prostatic hyperplasia Laser therapy for benign prostatic hyperplasia Laser therapy for benign prostatic hyperplasia Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Laser therapy for benign prostatic hyperplasia. Lansdale: HAYES, Inc.. 2010 Authors' objectives Laser prostatectomy is a minimally invasive therapy that uses laser-generated (...) heat to produce coagulation necrosis, to induce vaporization of prostate tissue, or allow for resection of prostate tissue. The laser device is introduced endoscopically through the urethra allowing direct visualization and access to the prostate gland. This procedure is intended as an alternative to traditional surgical transurethral resection of the prostate (TURP) for the treatment of benign prostatic hyperplasia (BPH). Project page URL Indexing Status Subject indexing assigned by CRD MeSH

2010 Health Technology Assessment (HTA) Database.

71. Benign prostatic hyperplasia.

Benign prostatic hyperplasia. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National Guideline Clearinghouse (NGC) has ended

2009 Finnish Medical Society Duodecim

72. Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review

Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

73. Photoselective vaporisation for benign prostatic hyperplasia: a rapid literature scan

Photoselective vaporisation for benign prostatic hyperplasia: a rapid literature scan Photoselective vaporisation for benign prostatic hyperplasia: a rapid literature scan Photoselective vaporisation for benign prostatic hyperplasia: a rapid literature scan Merlo G, Campbell S, Weston A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) Merlo G, Campbell S, Weston A. Photoselective vaporisation for benign prostatic hyperplasia: a rapid literature scan. Christchurch: Health Services Assessment Collaboration (HSAC). HSAC Report 2(11). 2009 Authors' conclusions The body of evidence suggests that PVP is a safe, effective, and durable treatment for LUTS secondary to BPH. The papers retrieved for this Rapid Literature Scan do not provide any evidence that PVP is associated with a decreased rate of adverse events Photoselective

2009 Health Technology Assessment (HTA) Database.

74. Non-drug local procedures for treatment of benign prostatic hyperplasia

Non-drug local procedures for treatment of benign prostatic hyperplasia Executive Summary IQWiG Reports - Commission No. N04-01 Non-drug local procedures for treatment of benign prostatic hyperplasia 1 1 Translation of the executive summary of the final report “Nichtmedikamentöse lokale Verfahren zur Behandlung der benignen Prostatahyperplasie” (Version 1.0; Status: 02.06.2008), Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely (...) the German original text is absolutely authoritative and legally binding. Executive summary of final report N04-01 Version 1.0 02.06.2008 Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Non-drug local procedures for treatment of benign prostatic hyperplasia Contracting agency: Federal Joint Committee Commission awarded on: 16.11.2004 Internal Commission No.: N04-01 Publisher’s address: Institute for Quality and Efficiency in Health Care Dillenburger Str. 27 51105

2008 Institute for Quality and Efficiency in Healthcare (IQWiG)

75. Photoselective vaporization of the prostate (PVP) for the treatment of benign prostatic hyperplasia (BPH)

Photoselective vaporization of the prostate (PVP) for the treatment of benign prostatic hyperplasia (BPH) Photoselective vaporization of the prostate (PVP) for the treatment of benign prostatic hyperplasia (BPH) Photoselective vaporization of the prostate (PVP) for the treatment of benign prostatic hyperplasia (BPH) Health Technology & Policy Unit Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation Health Technology & Policy Unit. Photoselective vaporization of the prostate (PVP) for the treatment of benign prostatic hyperplasia (BPH) . Edmonton: Health Technology&Policy Unit (HTPU). 2007 Authors' conclusions Four economic evaluations of PVP and TURP have been published in the past 4 years, from Canada, Switzerland, Australia and the United States. The common conclusion was that PVP is less costly per case that TURP. Our analysis shows that the cost

2007 Health Technology Assessment (HTA) Database.

76. Benign Prostatic Hyperplasia (BPH) Management in Primary Care

Benign Prostatic Hyperplasia (BPH) Management in Primary Care Mark Helfand, MD, MPH, FACP Staff Physician Portland VA Medical Center Portland, OR Tara Muzyk, Pharm.D. Clinical Pharmacist VA Southern Nevada Healthcare System Las Vegas, NV Mark Garzotto, MD Staff Physician, Urology Section Portland VA Medical Center Portland, OR Evidence Synthesis Pilot Program Benign Prostatic Hyperplasia (BPH) Management in Primary Care – Screening and Therapy Comparative Effectiveness Review Department (...) by users of these reports.TABLE OF CONTENTS EXECUTIVE SUMMARY 3 INTRODUCTION 5 CURRENT VA GUIDANCE 6 AUA GUIDELINES 6 SCOPE AND KEY QUESTIONS 8 ELIGIBILITY CRITERIA 8 METHODS 9 RESULTS 9 OVERVIEW 9 KEY QUESTION 1: For patients with BPH, what are the comparative benefits, harms, and efficacy of combination therapy with a 5-alpha-reductase inhibitor plus an alpha blocker versus either treatment alone? 9 KEY QUESTION 2: In head-to-head trials, for patients with benign prostatic hyperplasia (BPH), do

2007 Veterans Affairs Evidence-based Synthesis Program Reports

77. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis

The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

78. Long-term cost analysis of treatment options for benign prostatic hyperplasia in Norway Full Text available with Trip Pro

Long-term cost analysis of treatment options for benign prostatic hyperplasia in Norway Long-term cost analysis of treatment options for benign prostatic hyperplasia in Norway Long-term cost analysis of treatment options for benign prostatic hyperplasia in Norway Bjerklund Johansen T E, Istad J A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared 5-alpha reductase inhibitors (5-ARIS) and a surgical intervention for the treatment of benign prostatic hyperplasia (BPH). The 5-ARIS studies were dutasteride, finasteride and tamsulosin. The surgical intervention was transurethral resection of the prostate (TURP). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population

2007 NHS Economic Evaluation Database.

79. Saw palmetto for benign prostatic hyperplasia. Full Text available with Trip Pro

Saw palmetto for benign prostatic hyperplasia. Saw palmetto is used by over 2 million men in the United States for the treatment of benign prostatic hyperplasia and is commonly recommended as an alternative to drugs approved by the Food and Drug Administration.In this double-blind trial, we randomly assigned 225 men over the age of 49 years who had moderate-to-severe symptoms of benign prostatic hyperplasia to one year of treatment with saw palmetto extract (160 mg twice a day) or placebo (...) to 1.01), maximal urinary flow rate (mean difference, 0.43 ml per minute; 95 percent confidence interval, -0.52 to 1.38), prostate size, residual volume after voiding, quality of life, or serum prostate-specific antigen levels during the one-year study. The incidence of side effects was similar in the two groups.In this study, saw palmetto did not improve symptoms or objective measures of benign prostatic hyperplasia. (ClinicalTrials.gov number, NCT00037154.).Copyright 2006 Massachusetts Medical

2006 NEJM Controlled trial quality: predicted high

80. The thermo-expandable metallic stent for managing benign prostatic hyperplasia: a systematic review

The thermo-expandable metallic stent for managing benign prostatic hyperplasia: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.